Clarity Pharmaceuticals Ltd (ASX: CU6) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clarity Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$836.90 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
306.56 million
Earnings per share
-0.118
Dividend per share
N/A
Year To Date Return
42.02%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clarity Pharmaceuticals Ltd (ASX: CU6)
Latest News
Share Fallers
Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today
Share Market News
Why this exciting ASX biotech stock could be a future star
Healthcare Shares
1 ASX stock to consider buying that could be the next ResMed
Healthcare Shares
Why this ASX biotech stock could rise a massive 40%
Share Gainers
This ASX healthcare stock turned $20k into $140,000 in less than 2 years
Healthcare Shares
3 pharma shares outshining the ASX index today
Small Cap Shares
These small cap ASX shares can rise 30% to 80%: Bell Potter
Healthcare Shares
3 ASX healthcare shares that could make you a millionaire
Healthcare Shares
'The most exciting company in Australia': The ASX stock up 179% in 6 months
CU6 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
CU6 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 18 Apr 2024 | $2.71 | $0.02 | 0.74% | 453,782 | $2.70 | $2.71 | $2.61 |
| 17 Apr 2024 | $2.69 | $-0.02 | -0.74% | 289,925 | $2.70 | $2.73 | $2.64 |
| 16 Apr 2024 | $2.71 | $0.06 | 2.26% | 346,891 | $2.65 | $2.74 | $2.62 |
| 15 Apr 2024 | $2.65 | $-0.05 | -1.85% | 504,639 | $2.76 | $2.76 | $2.63 |
| 12 Apr 2024 | $2.70 | $-0.02 | -0.74% | 209,077 | $2.72 | $2.74 | $2.69 |
| 11 Apr 2024 | $2.72 | $-0.08 | -2.86% | 358,368 | $2.77 | $2.77 | $2.70 |
| 10 Apr 2024 | $2.80 | $0.03 | 1.08% | 626,634 | $2.78 | $2.82 | $2.77 |
| 09 Apr 2024 | $2.77 | $-0.03 | -1.07% | 860,823 | $2.80 | $2.80 | $2.74 |
| 08 Apr 2024 | $2.80 | $0.16 | 6.06% | 1,722,554 | $2.66 | $2.80 | $2.63 |
| 05 Apr 2024 | $2.64 | $-0.05 | -1.86% | 1,020,475 | $2.66 | $2.69 | $2.60 |
| 04 Apr 2024 | $2.69 | $-0.05 | -1.82% | 853,904 | $2.69 | $2.77 | $2.63 |
| 03 Apr 2024 | $2.74 | $-0.04 | -1.44% | 428,945 | $2.78 | $2.81 | $2.72 |
| 02 Apr 2024 | $2.78 | $0.03 | 1.09% | 475,199 | $2.76 | $2.81 | $2.73 |
| 28 Mar 2024 | $2.75 | $-0.09 | -3.17% | 1,224,489 | $2.73 | $2.80 | $2.60 |
| 22 Mar 2024 | $2.84 | $-0.10 | -3.40% | 597,302 | $2.94 | $2.94 | $2.77 |
| 21 Mar 2024 | $2.94 | $-0.05 | -1.67% | 528,451 | $2.99 | $2.99 | $2.87 |
| 20 Mar 2024 | $2.99 | $0.31 | 11.56% | 1,560,579 | $2.75 | $3.05 | $2.74 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 21 Mar 2024 | Thomas Ramdahl | Buy | 400,000 | $242,000 |
Exercise of options.
|
| 21 Mar 2024 | Thomas Ramdahl | Exercise | 400,000 | $242,000 |
Exercise of options.
|
| 12 Dec 2023 | Alan Taylor | Issued | 1,764,981 | $1,596,400 |
Issue of options. Black - Scholes model, VWAP
|
| 12 Dec 2023 | Colin Biggin | Issued | 928,988 | $840,846 |
Issue of options. Black-Scholes, VWAP, As per announcement on 14-12-2023
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Christopher Graham Roberts | Non-Executive Director | Mar 2016 |
Dr Roberts has more than 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career.
|
| Mr Robert Bain Thomas | Non-Executive Director | Aug 2021 |
Mr Thomas has a background in financial services and capital markets and has expertise in mergers & acquisitions and capital markets including advising on the IPOs of the Commonwealth Bank of Australia and Qantas. Mr Thomas is the former CEO of County NatWest Securities and the former CEO (and then Chairman) of Citi Corporate and Investment Bank Australasia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd (ultimately IOOF Ltd), TAL (Australia's largest life insurance company). Mr Thomas is the Chairman of AusBio Ltd, Grahger Retail Securities Pty Ltd and is a non-executive director of Biotron Limited and O'Connell Street Associates. He is a past non-executive director of Reva Medical Inc. and Virgin Australia.
|
| Ms Rosanne Elizabeth Robinson | Non-Executive Director | Oct 2010 |
Ms Robinson brings experience in the nuclear field and a range of commercial and operational expertise to the Group. She has over 25 years of experience in senior leadership and governance roles in public and private companies and government. Ms Robinson is the Chief Operating Officer of Cyclotek (Aust) Pty Ltd and previously General Manager Business Development at Australian Nuclear Science and Technology Organisation for over 13 years. Ms Robinson's knowledge of the nuclear medicine industry provides the Group with a clear vision across the dynamics of a rapidly evolving segment of the healthcare industry.
|
| Dr Alan John Taylor | Executive ChairmanExecutive Director | Nov 2013 |
Dr Taylor has 15 years of investment banking experience focused predominantly on the life sciences sector, and has expertise in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity Pharmaceuticals, Dr Taylor was an Executive Director of Inteq Limited, a boutique Australian investment bank.
|
| Dr Colin David Biggin | Chief Executive OfficerManaging Director | Oct 2019 |
Dr Biggin has more than 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo (radium-223 dichloride) for metastatic prostate cancer, which was approved by the US FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
|
| Dr Thomas Ramdahl | Non-Executive Director | Mar 2019 |
Dr Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and the first CEO of Algeta ASA. Dr Ramdahl has authored more than 40 publications and is a co-inventor of several patents. Dr Ramdahl currently serves as a non-executive direct of Precirix (Belgium)
|
| Mr Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
|
| David Green | Chief Financial Officer |
-
|
|
| Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Tm Ventures Pty Ltd | 18,788,460 | 7.18% |
| Cabbit Pty Ltd Atf Robwill Trust | 17,911,280 | 6.84% |
| National Nominees Limited | 16,737,583 | 6.39% |
| A.C.N. 136 437 913 Pty Ltd Atf The Taylor Family A/C | 13,266,660 | 5.07% |
| BNP Paribas Noms Pty Ltd | 10,077,537 | 3.85% |
| Argo Investments Limited | 9,247,447 | 3.53% |
| UBS Nominees Pty Ltd | 8,176,111 | 3.12% |
| Yarrawah Pty Ltd Atf Peter Henderson P/L S/F A/C | 7,803,450 | 2.98% |
| Vantres Pty Ltd Atf Asten Superannuation Fund | 7,487,340 | 2.86% |
| Charles Waite Morgan | 6,900,041 | 2.64% |
| Boorris Pty Ltd Atf Boorris Trust | 6,065,800 | 2.32% |
| Moore Family Nominee Pty Ltd Atf Moore Family Super Fund | 5,800,000 | 2.21% |
| Citicorp Nominees Pty Limited | 5,725,451 | 2.19% |
| Smarter Capital Pty Ltd | 5,004,543 | 1.91% |
| Kylaco Pty Ltd | 3,896,280 | 1.49% |
| Australian Nuclear Science And Technology Organisation | 3,599,920 | 1.37% |
| Pacific Custodians Pty Limited | 3,201,408 | 1.22% |
| Wyargine Holdings Pty Ltd Atf Shellcove Super Fund | 3,116,000 | 1.19% |
| Um Commercialisation Pty Ltd | 2,946,500 | 1.13% |
| Eight Pagodas Pty Ltd Atf Eight Pagodas Superannuation Fund | 2,768,320 | 1.06% |
